Association of British Clinical Diabetologists

Canagliflozin Nationwide Audit

 
Home Live ABCD audits of new therapies and devices All ABCD nationwide audits Future audits of new therapies ABCD worldwide audits
     

Above: Over 104 weeks canagliflozin led to durable reductions in HbA1c, that were superior to a sulphonylurea. But will this also be the finding in real clinical use? - click to enlarge

 

Above: Over 104 weeks canagliflozin use was associated with a significant reduction in weight compared to weight a increase associated with a sulphonylurea. But will this also be the finding in real clinical use?  click to enlarge

 

Above - canagliflozin significantly reduces systolic blood pressure compared to sitagliptin. Will there be evidence of effects on BP in real clinical use? - click to enlarge

 

Above: the overall population incidence of UTI adverse events was slightly higher with canagliflozin compared with placebo in clinical trials. It will be important to establish what we can about the safety of the agent in real clinical practice - click to enlarge

ABCD nationwide canagliflozin audit on N3

About the ABCD nationwide canagliflozin audit

With the launch of the canagliflozin audit, ABCD is now auditing two from new class of drugs for diabetes, the SGLT2 inhibitors. As with the ABCD GLP1-receptor agonist audits (exenatide, liraglutide and exenatide QW) it may be that patients being treated with the SGLT2 inhibitors in real clinical practice will be different from those in clinical trials and outcomes may also be different both in terms of safety and efficacy. As with the exenatide QW and dapagliflozin audits, this audit is again being hosted on N3 - the latest version of NHSnet. Access the on-line tool for the audit does require the user to be on N3 ie in an NHS hospital, GP surgery etc. The audit was launched at a meeting at the Royal College of Physicians on 24th January 2016. The audit has a number of objectives.

Web-based audit tool on N3
The audit tool for the canagliflozin audit is very similar to that being used for the dapagliflozin audit. This will make comparison between the data in the two audits and combining data for analysis of class an easy task. The tool is easy to use. Being on N3 it has optimum security for patient identifiable data with regard to your own patients, but anonymises the data when it is utilised in the national audit. There are some special features with regard to the data export both for your own local analysis and for the nationwide analysis. The export now allows you to choose which data to download for analysis as well as providing all data. It also allows you to choose to download the data aggregated to 2 monthly, 3 monthly, 4 monthly or 6 monthly time points.  The tool has the facility to detect data from the same patient entered in two sites (eg hospital and primary care) and to merge the data when exported - see centres and sites below. A new feature being introduced for this audit, to improve patient safety, is that Janssen's pharmacovigilance team will be alerted automatically of any serious adverse events. This is in addition to the usual advice that adverse events occurring in the UK should be reported to the yellow card scheme: www.mhra.gov.uk/yellowcard.

Structure of the audit centres and sites
For this audit the concept of centres and sites is utilised in the same way as in the exenatide QW and dapagliflozin audits. Typically a centre might be an NHS Trust. Sites might be hospitals associated with that Trust, and/or health centres or GP surgeries in the local vicinity. If set up in this structure, designated leaders of the local audit would be given access to download the anonymised data of all the patients associated with the centre for more powerful local analysis of data involving higher numbers. Findings so made through such local analysis could be put forward for further testing on the full national dataset.

Collect data on-line or via paper forms
The on-line audit tool is so easy to use that live data entry in clinic is a real option to be considered. Otherwise to facilitate data collection during clinics there are two paper forms which exactly match the data that can be entered into the audit tool. You can download and print these forms locally or order pre-printed data entry forms.

To download the forms to printout for use, use the following links:

Download first visit data entry form
Download follow up visit data entry form

Non ABCD members
Non ABCD members are welcome to take part in the audit and will be given access to the on-line audit tool when they
register for the audit.

Register to take part in the audit and access to the on-line tool
To register for the audit and be given access to the on-line tool on the ABCD website on N3 click here.

Northern Ireland and Worldwide
As Northern Ireland is not on N3, a non N3 version of the tool has been developed which can allow any country in the world to enrol at no cost and utilise the facilities. Any country, and centres in the country, may collect and analyse their own data which will then automatically become part of worldwide audit
.  For more information click here.

Further information
Further enquiries may be made to the ABCD nationwide audits database administrator of the project,
Melissa Cull
   Register for the canagliflozin audit: UK

Register for the canagliflozin audit: Northern Ireland and non-UK

Register simultaneously for ALL 3 SGLT2 audits: canagliflozin, dapagliflozin and empagliflozin

Access the on-line tool
(UK: you need to be on N3)

Access the worldwide on-line tool
(Northern Ireland and non-UK)

Canagliflozin audit objectives

Order preprinted data entry forms

Download first visit data entry form

Download follow up visit data entry form

Further information- contact us

Main ABCD homepage

     

The ABCD nationwide canagliflozin audit is an independent audit supported by an unrestricted grant from Janssen

Working to support high quality diabetes care in the UK